rethinkTHC Search
Menu
Study breakdown

Blocking a fatty acid transport protein reduced anxiety in rats through CB2 receptors in the prefrontal cortex

AnimalLow evidence
The takeaway

A novel FABP-5 inhibitor reduced anxiety behaviors in rats when injected into the prefrontal cortex, and this effect depended on CB2 cannabinoid receptor activation, revealing a new endocannabinoid-based anxiety mechanism.

Neuroscience researchers, anxiety disorder specialists, and drug development scientists exploring endocannabinoid targets.

Novel FABP5-CB2 receptor anxiety pathway identified in prefrontal cortex

What the researchers found

The FABP-5 inhibitor SBFI-103 reduced anxiety-like behaviors when administered to the rat prefrontal cortex. This anxiolytic effect was blocked by a CB2 receptor antagonist, identifying a novel FABP5-CB2 receptor pathway in anxiety regulation.

Why it matters

Current anxiety medications have significant limitations. Discovering a new endocannabinoid pathway (FABP5-CB2) in the prefrontal cortex that regulates anxiety could open a novel drug development avenue that avoids the psychoactive effects of THC.

The numbers in context

Acute intra-prefrontal cortex SBFI-103 reduced anxiety behaviors. CB2 receptor antagonist reversed the effect, confirming CB2 dependence.

How the study worked

Behavioral pharmacology in rats. SBFI-103 (FABP-5 inhibitor) was injected into the prelimbic prefrontal cortex. Anxiety assessed using standard behavioral tests. CB2 receptor antagonist used to determine mechanism.

What this study cannot tell us

Rat study with direct brain injection, not a clinically feasible route. Unknown whether systemic FABP-5 inhibition would produce the same effect. CB2 receptor role in brain function is still debated. Single behavioral paradigm.

How to read the evidence

Well-designed mechanistic animal study. Very early-stage finding with no clear path to clinical translation yet.

When this study was published

Published 2023.

The bigger picture

Most cannabinoid-anxiety research has focused on CB1 receptors and anandamide. The identification of a CB2-dependent pathway in the prefrontal cortex expands the potential target space for endocannabinoid-based anxiety therapies.

Questions still open

  • Would systemic FABP-5 inhibitors be anxiolytic without psychoactive effects? How does this CB2-dependent prefrontal pathway interact with CB1-mediated anxiety circuits?

Common questions

Could this lead to new anxiety medications?
Potentially. Targeting the FABP5-CB2 pathway could produce anxiolytic effects without the psychoactive properties of THC (which acts mainly through CB1). However, this is very early research in rats using direct brain injection, and many steps remain before any clinical application.
What is FABP-5 and why does it matter for anxiety?
FABP-5 (fatty acid binding protein 5) is a transport protein that carries endocannabinoids like anandamide to their degradation sites. Blocking FABP-5 increases endocannabinoid levels locally. This study found that the anxiety-reducing effect of FABP-5 inhibition in the prefrontal cortex depends on CB2 cannabinoid receptors.

Read the original research

Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex.

Cerebral cortex (New York, N.Y. : 1991), 33(6), 2470-2484

Citation

Uzuneser, Taygun C; Szkudlarek, Hanna J; Jones, Matthew J; Nashed, Mina G; Clement, Timothy; Wang, Hehe; Ojima, Iwao; Rushlow, Walter J; Laviolette, Steven R. (2023). Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex.. Cerebral cortex (New York, N.Y. : 1991), 33(6), 2470-2484. https://doi.org/10.1093/cercor/bhac220

Explore the wider topic